PL4566591T3 - Stała farmaceutyczna postać dawkowania zawierająca ezetymib i pitawastatynę - Google Patents
Stała farmaceutyczna postać dawkowania zawierająca ezetymib i pitawastatynęInfo
- Publication number
- PL4566591T3 PL4566591T3 PL23214816.3T PL23214816T PL4566591T3 PL 4566591 T3 PL4566591 T3 PL 4566591T3 PL 23214816 T PL23214816 T PL 23214816T PL 4566591 T3 PL4566591 T3 PL 4566591T3
- Authority
- PL
- Poland
- Prior art keywords
- ezetimible
- pitavastatin
- dosage form
- pharmaceutical dosage
- solid pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP23214816.3A EP4566591B1 (en) | 2023-12-07 | 2023-12-07 | SOLID PHARMACEUTICAL FORM CONTAINING EZETIMIBE AND PITAVASTATIN |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4566591T3 true PL4566591T3 (pl) | 2026-04-07 |
Family
ID=89121633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL23214816.3T PL4566591T3 (pl) | 2023-12-07 | 2023-12-07 | Stała farmaceutyczna postać dawkowania zawierająca ezetymib i pitawastatynę |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP4566591B1 (pl) |
| PL (1) | PL4566591T3 (pl) |
| PT (1) | PT4566591T (pl) |
| SI (1) | SI4566591T1 (pl) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1336714C (en) | 1987-08-20 | 1995-08-15 | Yoshihiro Fujikawa | Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis |
| US5631365A (en) | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US20060046996A1 (en) | 2004-08-31 | 2006-03-02 | Kowa Co., Ltd. | Method for treating hyperlipidemia |
| JP6937195B2 (ja) | 2017-09-01 | 2021-09-22 | 興和株式会社 | 医薬組成物 |
| JPWO2020178878A1 (pl) | 2019-03-01 | 2020-09-10 | ||
| JP2021008432A (ja) | 2019-07-01 | 2021-01-28 | 興和株式会社 | 医薬組成物 |
| US11833133B2 (en) | 2020-08-13 | 2023-12-05 | Orient Pharma Co., Ltd. | Solid oral pharmaceutical composition |
| CN112999178A (zh) | 2021-03-01 | 2021-06-22 | 乐普制药科技有限公司 | 一种依折麦布匹伐他汀钙复方双层片剂 |
-
2023
- 2023-12-07 PL PL23214816.3T patent/PL4566591T3/pl unknown
- 2023-12-07 SI SI202330067T patent/SI4566591T1/sl unknown
- 2023-12-07 EP EP23214816.3A patent/EP4566591B1/en active Active
- 2023-12-07 PT PT232148163T patent/PT4566591T/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI4566591T1 (sl) | 2026-02-27 |
| EP4566591A1 (en) | 2025-06-11 |
| PT4566591T (pt) | 2026-03-20 |
| EP4566591B1 (en) | 2025-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL284835A (en) | Pharmaceutical combination comprising tno155 and ribociclib | |
| EP4146198A4 (en) | Novel compositions of matter and pharmaceutical compositions | |
| EP4149460C0 (en) | THERAPEUTIC SOLID DOSAGE FORMS | |
| EP4183391A4 (en) | PHARMACEUTICAL COMPOSITION AND ITS USE | |
| PL3938047T3 (pl) | Zmostkowane tricykliczne związki karbamoilopirydonowe i ich zastosowanie farmaceutyczne | |
| EP4214183A4 (en) | PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS COMPRISING ANDROGEN RECEPTOR INHIBITORS AND USES THEREOF | |
| EP4149470A4 (en) | Pharmaceutical formulations and uses thereof | |
| EP4397663A4 (en) | 6-AMINOPYRAZOLOPYRIMIDINE COMPOUND AND ITS PHARMACEUTICAL USE | |
| EP4146247A4 (en) | PHARMACEUTICAL AND COSMETIC COMPOSITIONS COMPRISING SECRETOMES | |
| IL291191A (en) | Cdk inhibitors and their use as pharmaceuticals | |
| DK3727555T3 (da) | Oral delivery of active drug substances | |
| EP4074334A4 (en) | PHARMACEUTICAL COMPOSITION AND ITS USE | |
| IL284733A (en) | Pharmaceutical delivery compositions and uses thereof | |
| IL311331A (en) | Pharmaceutical composition and use thereof | |
| EP4375300A4 (en) | PHARMACEUTICAL COMPOSITION AND ITS USE | |
| EP3784214C0 (en) | ORAL LIQUID PHARMACEUTICAL DOSAGE FORM | |
| IL282591A (en) | Aminopeptidase a inhibitors and pharmaceutical compositions comprising the same | |
| CL2015003561A1 (es) | Composición farmacéutica para administración por vía oral para su uso para la prevención y/o el tratamiento de una enfermedad cardiovascular. | |
| IL312874A (en) | Pharmaceutical composition and use thereof | |
| EP4321537A4 (en) | Pharmaceutical composition and use thereof | |
| EP3893843C0 (en) | Pharmaceutical compositions of furosemide and their uses | |
| PL4566591T3 (pl) | Stała farmaceutyczna postać dawkowania zawierająca ezetymib i pitawastatynę | |
| EP3965739C0 (en) | DOSAGE FORMULATIONS OF OLEYL PHOSPHOCHOLINE TABLETS | |
| EP4384145C0 (en) | PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF KETAMINE DERIVATIVES | |
| EP4349366A4 (en) | PHARMACEUTICAL COMPOSITION |